Mark W. Hahn, Chief Financial Officer at Verona Pharma plc (VRNA), sold 400,000 shares at $11.40 ($4.6M) on 2025-06-11, disclosed to the SEC on 2025-06-13.
Scheduled sale ($4.6M) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| VRNA | SELL | 2025-05-05 | $7.0M | — | Filing → |
| VRNA | SELL | 2025-05-01 | $1.6M | — | Filing → |
| VRNA | SELL | 2024-12-06 | $8.5M | — | Filing → |